Fount of Information

TriLink BioTechnologies社 Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response




Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response

RNA-based vaccines offer several advantages over traditional ones, including faster production, simpler scale-up, and more rapid adaptability to new targets. These factors have proven critical in tackling the ongoing COVID-19 pandemic, allowing vaccines targeting SARS-CoV-2 to be developed in record time, while also enabling the rapid evolution of vaccination strategies as new strains of the virus emerge. Both Pfizer/BioNTech and Moderna received regulatory approval for their mRNA vaccine products within a year of the novel coronavirus first being sequenced, and many more RNA vaccines are currently in clinical trials...


Your partner for mRNA vaccine development

The recent clinical success of mRNA vaccines against SARS-CoV-2 paves the way for future vaccine development. Whether you are in the discovery phase or nearing GMP manufacturing, TriLink offers a solution to fit your mRNA vaccine program:

·    Plasmid manufacturing for use as an IVT template

·    Custom mRNA synthesis from RUO through GMP grade

·    CleanCap® capping technology for non-replicating mRNA and self-amplifying mRNA

Learn more about how TriLink can support your vaccine development program.

mRNA Vaccine Solutions.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。